ADC Therapeutics SA (ADCT) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
BIOPOLE EPALINGES, 1066 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 250,867 | 278,598 | |||
| Cash and cash equivalent | 250,867 | 278,598 | |||
| Inventory, net of allowances, customer advances and progress billings | 18,387 | 16,177 | |||
| Inventory | 18,387 | 16,177 | |||
| Other current assets | 9,450 | ||||
| Other undisclosed current assets | 28,686 | 41,516 | |||
| Total current assets: | 307,390 | 336,291 | |||
| Noncurrent Assets | |||||
| Inventory, Noncurrent | |||||
| Operating lease, right-of-use asset | 8,354 | 10,511 | |||
| Property, plant, and equipment, after accumulated depreciation, depletion, and amortization | 5,075 | 5,622 | |||
| Long-term investments and receivables | 1,647 | ||||
| Long-term investments | 1,647 | ||||
| Other noncurrent assets | 1,161 | 711 | |||
| Total noncurrent assets: | 14,590 | 18,491 | |||
| TOTAL ASSETS: | 321,980 | 354,782 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 80,469 | 66,203 | |||
| Accounts payable | 18,029 | 15,569 | |||
| Accrued liabilities | 62,440 | 50,634 | |||
| Debt | |||||
| Other undisclosed current liabilities | 1,467 | ||||
| Total current liabilities: | 80,469 | 67,670 | |||
| Noncurrent Liabilities | |||||
| Long-term debt and lease obligation | 113,632 | 112,730 | |||
| Long-term debt, excluding current maturities | 113,632 | 112,730 | |||
| Liabilities, other than long-term debt | 12,340 | 20,391 | |||
| Deferred income tax liabilities | 1,912 | 1,332 | |||
| Other liabilities | 2,433 | 8,879 | |||
| Operating lease, liability | 7,995 | 10,180 | |||
| Other undisclosed noncurrent liabilities | 318,181 | 302,240 | |||
| Total noncurrent liabilities: | 444,153 | 435,361 | |||
| Total liabilities: | 524,622 | 503,031 | |||
| Equity | |||||
| Equity, attributable to parent | (202,642) | (148,249) | |||
| Common stock | 8,425 | 7,312 | |||
| Treasury stock, value | (220) | (541) | |||
| Additional paid in capital | 1,283,892 | 1,180,545 | |||
| Accumulated other comprehensive loss | (1,421) | (93) | |||
| Accumulated deficit | (1,493,318) | (1,335,472) | |||
| Total equity: | (202,642) | (148,249) | |||
| TOTAL LIABILITIES AND EQUITY: | 321,980 | 354,782 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|
| Revenues | 70,837 | 69,558 | ||
| Cost of revenue | (5,949) | (2,529) | ||
| Cost of product and service sold | (1,518) | (1,608) | ||
| Gross profit: | 64,888 | 67,029 | ||
| Operating expenses | (195,542) | (233,015) | ||
| Operating loss: | (130,654) | (165,986) | ||
| Nonoperating expense | (25,482) | (29,433) | ||
| Other nonoperating income | 12,457 | 6,352 | ||
| Interest and debt expense | (50,211) | (46,325) | ||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 50,211 | 46,325 | ||
| Loss from continuing operations before equity method investments, income taxes: | (156,136) | (195,419) | ||
| Loss from equity method investments | (1,544) | (5,528) | ||
| Loss from continuing operations before income taxes: | (157,680) | (200,947) | ||
| Income tax expense | (166) | (39,106) | ||
| Net loss available to common stockholders, diluted: | (157,846) | (240,053) | ||
Comprehensive Income ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|
| Net loss: | (157,846) | (240,053) | ||
| Comprehensive loss: | (157,846) | (240,053) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (1,332) | (1,916) | ||
| Comprehensive loss, net of tax, attributable to parent: | (159,178) | (241,969) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.